Phase III Trial Comparing UFT + PSK to UFT + LV in Stage IIB, III Colorectal Cancer (MCSGO-CCTG)

Overview

Journal Surg Today

Specialty General Surgery

Date 2017 Jun 22

PMID 28634730

Citations 10

Authors

Yasuhiro Miyake

Junichi Nishimura

Takeshi Kato

Masataka Ikeda

Masaki Tsujie

Taishi Hata

Ichiro Takemasa

Tsunekazu Mizushima

Hirofumi Yamamoto

Mitsugu Sekimoto

Riichiro Nezu

Yuichiro Doki

Masaki Mori

Affiliations

Soon will be listed here.

Abstract

Purpose: Oral adjuvant uracil and tegafur plus leucovorin (UFT/LV) is not inferior to standard weekly fluorouracil and folinate for stage II/III colon cancer. However, protein-bound polysaccharide K (PSK) has been evaluated as postoperative adjuvant therapy for colorectal cancer. This report is the first of MCSGO-CCTG, which compared UFT/LV to UFT/PSK as adjuvant chemotherapy for stage IIB or III colorectal cancer in patients who had undergone Japanese D2/D3 lymph node dissection.

Methods: The primary endpoint was the 3-year disease-free survival (DFS). A randomized non-inferiority study compared UFT/LV to UFT/PSK. The overall survival, adverse events, compliance, and quality of life were also investigated as the secondary endpoints.

Results: Between March 2006 and December 2010, 357 patients were randomized to UFT/PSK (n = 178) or UFT/LV (n = 179) (median age 65 years, colon/rectum 67.4/32.6%, stage IIB/IIIA/IIIB/IIIC 11.1/15.7/55.0/18.2%). The 3-year DFS rate was 82.3% in those receiving UFT/LV and 72.1% in those receiving UFT/PSK. The non-inferiority of UFT/PSK adjuvant therapy to UFT/LV therapy was not verified (-9.06%, 90% confidence interval -17.06 to -1.06%). The 3-year overall survival rate was 95.4% in those receiving UFT/LV and 90.7% in those receiving UFT/PSK.

Conclusions: As adjuvant chemotherapy for stage IIB and III colorectal cancer patients, UFT/PSK adjuvant therapy was not non-inferior to UFT/LV therapy with respect to the DFS.

Citing Articles

Using oral tegafur/uracil (UFT) plus leucovorin as adjuvant chemotherapy in stage II colorectal cancer: a propensity score matching study from Taiwan.

Yu Y, Tseng W, Liao C, Yeh C, Chen H, Liu Y BMC Cancer. 2023; 23(1):900.

PMID: 37749535 PMC: 10518963. DOI: 10.1186/s12885-023-11310-6.

The Health and Clinical Benefits of Medicinal Fungi.

Hobbs C Adv Biochem Eng Biotechnol. 2023; 184:285-356.

PMID: 37468715 DOI: 10.1007/10_2023_230.

Therapeutic Effects of Medicinal Mushrooms on Gastric, Breast, and Colorectal Cancer: A Scoping Review.

Dan A, Swain R, Belonce S, Jacobs R Cureus. 2023; 15(4):e37574.

PMID: 37193480 PMC: 10183216. DOI: 10.7759/cureus.37574.

Coriolus (Trametes) versicolor mushroom to reduce adverse effects from chemotherapy or radiotherapy in people with colorectal cancer.

Pilkington K, Wieland L, Teng L, Jin X, Storey D, Liu J Cochrane Database Syst Rev. 2022; 11():CD012053.

PMID: 36445793 PMC: 9707730. DOI: 10.1002/14651858.CD012053.pub2.

Mushroom Polysaccharide-Assisted Anticarcinogenic Mycotherapy: Reviewing Its Clinical Trials.

Sivanesan I, Muthu M, Gopal J, Oh J Molecules. 2022; 27(13).

PMID: 35807336 PMC: 9267963. DOI: 10.3390/molecules27134090.

References

Sadahiro S, Suzuki T, Maeda Y, Tanaka A, Kamijo A, Murayama C . Effects of preoperative immunochemoradiotherapy and chemoradiotherapy on immune responses in patients with rectal adenocarcinoma. Anticancer Res. 2010; 30(3):993-9. View

Maehara Y, Moriguchi S, Sakaguchi Y, Emi Y, Kohnoe S, Tsujitani S . Adjuvant chemotherapy enhances long-term survival of patients with advanced gastric cancer following curative resection. J Surg Oncol. 1990; 45(3):169-72. DOI: 10.1002/jso.2930450307. View

Mieno H, Yamashita K, Hosoda K, Moriya H, Higuchi K, Azuma M . Conversion surgery after combination chemotherapy of docetaxel, cisplatin and S-1 (DCS) for far-advanced gastric cancer. Surg Today. 2017; 47(10):1249-1258. DOI: 10.1007/s00595-017-1512-z. View

Jimenez-Medina E, Berruguilla E, Romero I, Algarra I, Collado A, Garrido F . The immunomodulator PSK induces in vitro cytotoxic activity in tumour cell lines via arrest of cell cycle and induction of apoptosis. BMC Cancer. 2008; 8:78. PMC: 2291471. DOI: 10.1186/1471-2407-8-78. View

Lembersky B, Wieand H, Petrelli N, OConnell M, Colangelo L, Smith R . Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol. 2006; 24(13):2059-64. DOI: 10.1200/JCO.2005.04.7498. View

Beppu N, Yoshie H, Kimura F, Aihara T, Doi H, Kamikonya N . The short-term outcomes of induction SOX (S-1 + oxaliplatin) ± cetuximab chemotherapy followed by short-course chemoradiotherapy in patients with poor-risk locally advanced rectal cancer. Surg Today. 2015; 46(10):1123-31. DOI: 10.1007/s00595-015-1284-2. View

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

Ito K, Nakazato H, Koike A, Takagi H, Saji S, Baba S . Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. A randomized controlled trial for 7-year follow-up. Int J Colorectal Dis. 2003; 19(2):157-64. DOI: 10.1007/s00384-003-0532-x. View

Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y . Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol. 2011; 17(1):1-29. DOI: 10.1007/s10147-011-0315-2. View

10.

Ohwada S, Kawate S, Ikeya T, Yokomori T, Kusaba T, Roppongi T . Adjuvant therapy with protein-bound polysaccharide K and tegafur uracil in patients with stage II or III colorectal cancer: randomized, controlled trial. Dis Colon Rectum. 2003; 46(8):1060-8. DOI: 10.1007/s10350-004-7281-y. View

11.

Okuzawa M, Shinohara H, Kobayashi T, Iwamoto M, Toyoda M, Tanigawa N . PSK, a protein-bound polysaccharide, overcomes defective maturation of dendritic cells exposed to tumor-derived factors in vitro. Int J Oncol. 2002; 20(6):1189-95. View

12.

Ooshiro M, Sugishita Y, Tanaka H, Koide K, Nagashima M, Katoh R . Regulation of perioperative immunological changes following laparotomy: effects of biological response modifier (BRM) on surgical stress. Immunol Lett. 2004; 93(1):33-8. DOI: 10.1016/j.imlet.2004.01.008. View

13.

Ono Y, Hayashida T, Konagai A, Okazaki H, Miyao K, Kawachi S . Direct inhibition of the transforming growth factor-β pathway by protein-bound polysaccharide through inactivation of Smad2 signaling. Cancer Sci. 2011; 103(2):317-24. DOI: 10.1111/j.1349-7006.2011.02133.x. View

14.

Ohwada S, Ikeya T, Yokomori T, Kusaba T, Roppongi T, Takahashi T . Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study. Br J Cancer. 2004; 90(5):1003-10. PMC: 2409633. DOI: 10.1038/sj.bjc.6601619. View

15.

Hamaguchi T, Shirao K, Moriya Y, Yoshida S, Kodaira S, Ohashi Y . Final results of randomized trials by the National Surgical Adjuvant Study of Colorectal Cancer (NSAS-CC). Cancer Chemother Pharmacol. 2010; 67(3):587-96. DOI: 10.1007/s00280-010-1358-1. View

16.

Ward S, Kaltenthaler E, Cowan J, Marples M, Orr B, Seymour M . The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. Br J Cancer. 2006; 95(1):27-34. PMC: 2360498. DOI: 10.1038/sj.bjc.6603215. View

17.

Kuebler J, Wieand H, OConnell M, Smith R, Colangelo L, Yothers G . Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007; 25(16):2198-204. DOI: 10.1200/JCO.2006.08.2974. View

18.

Honma Y, Yamada Y, Terazawa T, Takashima A, Iwasa S, Kato K . Feasibility of neoadjuvant S-1 and oxaliplatin followed by surgery for resectable advanced gastric adenocarcinoma. Surg Today. 2015; 46(9):1076-82. DOI: 10.1007/s00595-015-1276-2. View

19.

MOERTEL C, Fleming T, Macdonald J, Haller D, Laurie J, Goodman P . Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990; 322(6):352-8. DOI: 10.1056/NEJM199002083220602. View

20.

Haller D, Tabernero J, Maroun J, De Braud F, Price T, Van Cutsem E . Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011; 29(11):1465-71. DOI: 10.1200/JCO.2010.33.6297. View